Compare Medpace Holdings Inc (MEDP) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Wendys Co — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Wendys Co trades at $7.85 (market cap $1.50B). The key difference: Medpace Holdings Inc is far larger — about 10.1× Wendys Co's market cap, and Wendys Co pays a 7.13% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | WEN | |
|---|---|---|
Market Cap | $15.08B | $1.50B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $11.33 |
52-Week Low | $308.88 | $6.17 |
Enterprise Value | $14.55B | $5.31B |
Dividend Yield | — | 7.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Wendy's (WEN) trades at $7.805, up 0.58% with a bullish technical signal and recent earnings beats. The stock shows attractive valuation metrics with P/E of 10.07 and P/S of 0.68, though net margins have declined to 6.77%. Recent news highlights Project Fresh initiatives and China expansion plans, while the company maintains a $0.14 dividend payment scheduled for June 2026.
WEN presents a mixed outlook with strong valuation appeal and dividend yield offset by margin pressures and declining earnings. The stock's 28% monthly gain reflects retail investor enthusiasm, but fundamental challenges require careful monitoring of turnaround execution and competitive positioning in the crowded fast-food sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
